Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.15 -0.75% 19.85 257,097 12:20:59
Bid Price Offer Price High Price Low Price Open Price
19.70 20.00 20.35 19.85 20.35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 78.20 8.07 1.11 17.9 127
Last Trade Time Trade Type Trade Size Trade Price Currency
16:16:30 O 50,000 19.899 GBX

Allergy Therapeutics (AGY) Latest News

More Allergy Therapeutics News
Allergy Therapeutics Investors    Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics Forums and Chat

Date Time Title Posts
19/1/202113:16Allergy Therapeutics - AGY -3,980
14/7/201620:04Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY)1
16/12/201510:24Allergy Therapeutics-Transforming Allergy Treatment26
03/2/201213:58Ready to ROCKET?-
04/12/200512:00AGY - Allergy Therapeutics79

Add a New Thread

Allergy Therapeutics (AGY) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-20 16:16:3119.9050,0009,949.50O
2021-01-20 16:12:4119.9012,5002,487.50O
2021-01-20 15:34:1619.71469.07O
2021-01-20 15:09:2419.99224.40O
2021-01-20 15:05:2519.7713,0002,570.10O
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

Allergy Therapeutics Daily Update: Allergy Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 20p.
Allergy Therapeutics Plc has a 4 week average price of 14.75p and a 12 week average price of 12.75p.
The 1 year high share price is 21.75p while the 1 year low share price is currently 7.38p.
There are currently 640,792,164 shares in issue and the average daily traded volume is 1,352,914 shares. The market capitalisation of Allergy Therapeutics Plc is £127,197,244.55.
wizzkid211: Allergy Therapeutics PLC Initiation of peanut allergy biomarker study January 05 2021 - 02:00AM UK Regulatory (RNS & others) Alert Print Share On Facebook TIDMAGY RNS Number : 5198K Allergy Therapeutics PLC 05 January 2021 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Allergy Therapeutics initiates peanut allergy biomarker study with Imperial College London to confirm potential of novel peanut vaccine candidate - Ex-vivo biomarker study to evaluate VLP-based peanut allergy vaccine candidate's hypoallergic potential and potent immune response - Findings to support peanut clinical programme with first-in-human trial on track for 2021 - Short-course vaccine candidate represents significant differentiated opportunity in $8bn worldwide food allergy market - IND application to United States Food and Drug Administration expected in 2021 5 January 2021 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces that an ex-vivo biomarker study of blood samples from peanut allergy patients has begun at Imperial College London. The study aims to evaluate the Group's novel virus like particle (VLP) based peanut allergy vaccine candidate, to confirm its hypoallergic potential and its potent immune response. The study at Imperial College London, using human samples and an extensive set of functional and molecular biomarkers, will provide Allergy Therapeutics with important information to establish the starting dose for its first-in-human Phase I study. The data will also act as an early clinical predictor of efficacy of the VLP platform and support the acceptance of the Investigational New Drug (IND) application and a successful Phase I trial outcome. The submission of an IND application to the United States Food and Drug Administration (FDA) for that study is expected in 2021. Allergy Therapeutic's peanut allergy vaccine programme is supported by a strong preclinical research package, providing pre-clinical proof of concept for sustained immunity and protection against peanut anaphylaxis after a single vaccination. Importantly, in contrast to current treatment approaches such as desensitisation via oral administration or transdermal patches, which require daily dosing over several years, it is anticipated that the Group's next-generation VLP-based peanut vaccine candidate will use only 3 injections to induce sustained protection. The potential of an effective short-course peanut allergy vaccine represents a significant opportunity in the $8 billion worldwide food allergy market(1) . Prevalence of peanut allergy in Western countries is on the rise and currently ranges from 1.4-3% of children(2) and, in the US, peanut allergy affects an estimated 1.2% of the overall US population(3) with 1 in 4 children with a peanut allergy requiring a hospital visit each year(4) . In parallel with the peanut allergy human biomarker study, a broader research project with Imperial College London has also commenced, focussing on the selection, measurement and analysis of pre-clinical and clinical biomarkers for allergen immunotherapy products across Allergy Therapeutics' portfolio. Clinical trials in the allergy immunotherapy area often pose challenges with interpretation as they rely on subjective non-validated endpoints. There is therefore an opportunity to explore alternative, more objective measures of success and develop a greater understanding of the underlying science in this important area. Under this collaboration agreement, researchers will examine samples from the Group's ongoing Grass MATA MPL exploratory field study (G309), and the pre-clinical and clinical development programme for the Group's VLP-based peanut allergy vaccine candidate. Changes in an extensive set of established and innovative biomarkers will be analysed at baseline and throughout treatment with each of the allergen immunotherapies. Manuel Llobet, CEO of Allergy Therapeutics , stated: "A safe and effective short-course peanut allergy vaccine would be a significant breakthrough product, offering life-changing benefits to sufferers affected by this condition. The data we have generated so far for our peanut vaccine candidate give us confidence in its potential and through this study we have an opportunity to build on that confidence and provide our upcoming Phase I study with the greatest chances of success. "At Allergy Therapeutics we are passionate about progressing the science around allergy immunotherapies. Our collaboration with Imperial College London, who are one of the foremost experts in this field, will equip us with a greater depth of knowledge of allergy biomarkers and their relationship to clinical outcomes, which will be applied to future clinical trials and aid in the development of our allergy immunotherapy pipeline."
jimmyloser: As we approach the rag end of another trading year, I note that both AGY and FUM are trading at exactly the same price this morning. Both appear to hold products in their portfolio's that could well be a game changer in 2021. Perhap's this is harsh, but AGY seem to be permanently in the 'could' phase whilst FUM have time on their hands. I currently do not hold FUM, but for fun will buy some. Let's see where both are at, come the end of March! dyor/impo
a1samu: A share fluctuates so much because of infrequent good news, mistrust of the management and mindless management of the share price! If shares were controlled and any surplus absorbed, MM would have no chance to mess it about, which they do to their own hearts delight with this one! Besides, nobody wants this share because of lack of any inspiration or vision of the future, so this just drifts and drifts as it will continue to do so. The price went up to over 20p in anticipation of the recent announcement, why should it drift so seriously if there was such a convincing story to tell? It should continue upwards if the market believed the story of the management.
a1samu: What matters is what the market says through the share price and the market says this is rubbish! And on top nobody wants this share!
audigger: It could be. However, whilst Palforzia is an ongoing treatment to be used in conjunction with peanut avoidance and in of itself poses a risk of anaphylaxis, AGY's peanut vaccine is potentially a cure and appears not to pose an anaphylactic risk itself. As published by AGY in January of this year "The fact that one injection against a single allergen was sufficient to induce protection against a whole peanut allergen mixture has never been described before and is described in the JACI paper as striking and could be applied in different relevant allergies. In addition, the vaccine proved to be hypo-allergenic as previously described, which in peanut allergy is a vital characteristic to avoid anaphylactic reactions upon dosing and to increase compliance." So my take on this is that what AGY have goes way beyond what Palforzia potentially offers. Usually I have added on the lows especially at 7p as there is a history of it hitting 7p and then quite quickly bouncing back to 14p and beyond but on this occasion I was indecisive which may prove costly. No doubt we still have a roller coaster to ride but the upsides are potentially very significant. But as we know, it can easily tank on bad news. Here's hoping the breakout continues this week
jimmyloser: My, oh, my!.................... is this why our share price is rising like a Mary Berry sponge and............... COP THE PRICE PAID!!!!!!!!!! I won't sleep ;-) DYOR
wizzkid211: Allergy Therapeutics PLC AGY secures VLP technology platform September 03 2020 - 02:00AM UK Regulatory (RNS & others) Alert Print Share On Facebook TIDMAGY RNS Number : 8818X Allergy Therapeutics PLC 03 September 2020 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group"), Saiba AG ("Saiba") and DeepVax GmbH ("DeepVax") Allergy Therapeutics secures virus-like particle ("VLP") technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH - Group to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findings 3 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field. Allergy therapeutics (the Group) entered into an exclusive licence agreement with Saiba AG and DeepVax GmbH to use their patented VLP technology platform to develop and commercialise vaccines targeting solid cancer tumours, atopic dermatitis, asthma, and psoriasis.
a1samu: Some reasons why the share price is improving! Allergy Therapeutics PLC 15 July 2020 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Trading Update - Strong 2020 performance despite COVID-19 challenge - Earnings above market expectations - Net revenue of GBP78.2million representing 6% annual growth - Strong cash balance of GBP37.0 million - Phase I Peanut program fully funded from existing resources - Licencing deal signed for new oral treatment, ImmunoBON - COVID-19 diagnostic facility approved by Spanish authorities 15 July 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2020 ahead of its Preliminary Results to be announced on 23 September 2020. Financials The Group now expects earnings for the full year 2020 to be ahead of market expectations as announced on 24 June 2020. Net revenue is expected to be GBP78.2million (2019: GBP73.7million) representing 6% annual growth (7% growth on a constant currency basis) reflective of a very robust performance in challenging circumstances. Operating efficiencies and timing of the research and development spend have led to strong overall performance with the Group likely to report a significant, positive net income for the year. Due to the Group's strong performance, the Executive Management has taken the decision to repay all UK furlough monies claimed back to the government. The cash balance at 30 June 2020 was GBP37.0 million (30 June 2019: GBP27.4 million). The Group's total bank loan debt was GBP3.8 million (30 June 2019: GBP2.4 million). Based on current assumptions, the Group expects to be able to fully fund the upcoming Grass MATA MPL pilot and pivotal Phase III field studies and the Phase I Peanut programme with existing cash resources and a small amount of additional debt. Response to COVID-19 and Commercial Update The Group has coped well with the challenge presented by COVID-19. After an initial decline, sales improved and have only been moderately affected due to patients not visiting clinics and hospitals. Trading in Southern Europe has been more heavily impacted than in Northern Europe, owing to the greater number of allergy clinics located within hospitals in Southern Europe. The sales and marketing team across Europe has responded rapidly to provide broad support to doctors, hospitals and patients. Encouragingly, the easing of restrictions is reflected in the final month of the year, with sales returning to previous levels. From the beginning of the COVID-19 outbreak, the Group has taken steps to ensure the safety of its employees. This was achieved, in part, by implementing social distancing measures within the Group's operations and splitting vital functions into separate teams to minimise the risk of workers becoming ill and slowing production and transport across the continent. Throughout the COVID-19 situation, the Group has maintained a constant supply of its products across all markets with no disruption in the supply chain. All areas of the business have reacted well to the challenges of COVID-19, with approximately two-thirds of staff working remotely. Clear communication with internal and external stakeholders and a strong collaborative approach in line with the Group's values and behaviours, have helped to ensure minimum disruption. COVID -19 Diagnostic Facility In response to the urgent need to increase the global capacity to diagnose infected COVID-19 patients, the Group has invested capital into expanding its microbiological diagnostic facilities in Spain, by incorporating an RT-PCR based SARS-COV-2 diagnostic test into its portfolio. The RT-PCR technique can detect a fragment of RNA (the genetic material) derived from the SARS-COV-2 virus to determine if the patient is currently infected. The Group's expanded microbiology facilities in Alcal√°, named AT Immunolab, have been authorised by Spanish Health Authorities and will provide support in this healthcare crisis helping healthcare providers and patients in this difficult situation. The project has been set up in a significantly accelerated timeframe and received financing from the Centre for the Development of Industrial Technology and the Technology Fund, from the Ministry of Science, Innovation and Universities of Spain. AT Immunolab began SARS-COV-2 testing in the first week of July and, at full capacity, is expected be able to perform 200,000 tests a year. Pipeline Previously communicated R&D plans continue to be executed and the Grass MATA MPL clinical programme is expected to start next month as planned, with the pilot field study in about 150 adults to be recruited in the US and Europe. The study will implement COVID-19 related procedures, flexibility and strategies to minimise the impact of COVID-19. Limited impact on clinical operations or regulatory activities is expected. The Group has signed a knowledge-sharing agreement with Saiba AG, owners of the virus-like particle (VLP) platform currently licensed to Allergy Therapeutics for allergy indications, to assist with the development of Saiba's COVID-19 vaccine candidates. The agreement has the potential to benefit the Group in the future, by supplying pre-clinical and clinical data using the same novel VLP platform to support the Group's peanut vaccine candidate programme. The Group has also signed a commercial agreement with Biomedical International R+D GmbH for the exclusive rights to ImmunoBON, a patented protein-based oral treatment which was developed to replicate the reduction in incidence of allergy as seen by those who live on a farm with livestock, the so-called "farm effect". In a preclinical study programme, the immunogenicity of the protein formulation with the selected ligands was proven, as well as the capacity to prevent allergic sensitisation(1-5) . At the scientific congress of the European Academy of Allergy and Clinical Immunology in June 2020, two poster presentations demonstrated that the product significantly reduced allergic symptoms in a mouse model(6) , and also among patients in a double-blind placebo controlled pilot study(7) when compared to placebo treatment. Additionally, a recently completed study in an allergen exposure chamber (European Centre for Allergy Research Foundation, Berlin, Germany) revealed significant improvement in allergy symptoms in house dust mite allergic patients (data on file).The product will initially be available in Germany with roll out across the rest of Europe to follow. Manuel Llobet, CEO at Allergy Therapeutics , stated: "Our focus during the COVID-19 pandemic has been the safety and well-being of all of our employees, partners and customers and I am proud of our robust and rapid response to the challenges presented during this time. When the outbreak started in Europe, we made a commitment as a group to leverage our strengths. Our business has put in place new efficiencies, highlighting our resilience and agility in times of change and we are thriving as a result. Our plans to develop a strong R&D pipeline remains on track and our two recently signed agreements with partners provides exciting new opportunities for our VLP technology and our oral treatment offerings for allergy patients. I am especially proud of our team and would like to thank them for their unwavering commitment and desire to drive the business forward." This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014. -S - For further information, please contact: Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Nick Wykeman, Chief Financial Officer Panmure Gordon +44 (0) 20 7886 2500 Freddy Crossley, Emma Earl, Corporate Finance James Stearns, Corporate Broking Consilium Strategic Communications +44 20 3709 5700 Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser Stern Investor Relations, Inc. +1 212 362 1200 Christina Tartaglia
jimmyloser: This is indeed good to see, I guess it was a case of the share price being over hammered. The management did what they had to in cases like this and just got on with making sure that the business delivered. They and we have been through a very tough time, but patience and belief will be and is being rewarded. Considering the box of tricks that they have up their sleeves, this lowly share price remains a mystery to me.............but for how long? (Yes, I have been buying solidly) dyor/impo
hedgehog 100: AGY's next financial year, i.e. July 2020 - June 2021, starts in just a week, and will see several important clinical trials: 04/03/2020 07:00 UK Regulatory (RNS & others) Allergy Therapeutics PLC Half-year Report " ... Outlook This calendar year is key in order to prepare for several important trials for the 2021 financial year. ..." But unlike most biotechs, AGY's strong cash position and trading gives it very solid value underpinning, meaning that the potential huge upside from trials success is 'in for free'. With a big bonus being potential involvement in COVID-19 vaccines. And I would expect an RNS on that last point soon. Indeed I believe that today's trading update 'paves the way' for a COVID-19 RNS. Similar to ODX in April, where a trading upate was followed a week later by a COVID-19 RNS. And during April the ODX share price multibagged. 02/04/2020 07:00 UK Regulatory (RNS & others) Omega Diagnostics Group PLC Trading Update 09/04/2020 07:00 UK Regulatory (RNS & others) Omega Diagnostics Group PLC COVID-19 Consortium MOU
Allergy Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210121 03:08:12